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MaBACKGROUND Worsening renal function (WRF) associated with renin-angiotensin-aldosterone system (RAAS)
inhibition does not confer excess risk in heart failure patients with reduced ejection fraction (HFrEF).
OBJECTIVES The goal of this study was to investigate the relationship between WRF and outcomes in heart failure
patients with preserved ejection fraction (HFpEF) and the interaction with RAAS blockade.
METHODS In 3,595 patients included in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction)
trial, change in estimated glomerular ﬁltration rate (eGFR) and development of WRF after initiation of irbesartan or
placebo were examined. We examined the association between WRF and the ﬁrst occurrence of cardiovascular death or
heart failure hospitalization (primary outcome in this analysis) and the interaction with randomized treatment.
RESULTS Estimated GFR decreased early with irbesartan treatment and remained signiﬁcantly lower than in the placebo
group. WRF developed in 229 (6.4%) patients and occurred more frequently with irbesartan treatment (8% vs. 4%).
Overall, WRF was associated with an increased risk of the primary outcome (adjusted hazard ratio [HR]: 1.43; 95%
conﬁdence interval [CI]: 1.10 to 1.85; p ¼ 0.008). Although the risk related to WRF was greater in the irbesartan group
(HR: 1.66; 95% CI: 1.21 to 2.28; p ¼ 0.002) than with placebo (HR: 1.09; 95% CI: 0.66 to 1.79; p ¼ 0.73), the interaction
between treatment and WRF on outcome was not signiﬁcant in an adjusted analysis.
CONCLUSIONS The incidence of WRF in HFpEF was similar to that previously reported in HFrEF but more frequent with
irbesartan than with placebo. WRF after initiation of irbesartan treatment in HFpEF was associated with excess risk, in
contrast to WRF occurring with RAAS blockade in HFrEF. (J Am Coll Cardiol 2014;64:1106–13) © 2014 by the American
College of Cardiology Foundation.m the *British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences,
iversity of Glasgow, Glasgow, United Kingdom; yUniversity of Groningen, Department of Cardiology, University Medical Center
oningen, Groningen, the Netherlands; zVeterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota;
niversité Paris 6 and Pitié–Salpêtrière Hospital, Paris, France; kHamilton Health Sciences, McMaster University, Hamilton,
tario, Canada; {Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South
rolina; #University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California;
d the **Georgetown University andWashington DC Veterans Affairs Medical Center, Washington, DC. Dr. Damman is supported
the Netherlands Heart Institute (ICIN) and a European Society of Cardiology Heart Failure Association research grant. Drs. Zile,
ssie, Carson, Anand, McMurray, McKelvie, and Komajda have served as consultants and received honoraria from Bristol-Myers
uibb for their roles in conducting the I-PRESERVE trial, including serving on the coordinating committee, executive committee,
d endpoint committee. Dr. Komajda has performed consulting/advisory activities for Servier, Menarini, Bristol-Myers Squibb,
d AstraZeneca. Dr. Massie has received grant support from Bristol-Myers Squibb, Sanoﬁ-Aventis, Merck & Co.; consulting fees
m Bristol-Myers Squibb, Sanoﬁ-Aventis, Merck & Co., Duke Clinical Research Institute, Momentum Research, Novartis,
xoSmithKline, Scias/Johnson & Johnson, Corthera, and Niles Therapeutics; and lecture fees from Merck & Co. Dr. Perez has
orted that she has no relationships relevant to the contents of this paper to disclose.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received November 29, 2013; revised manuscript received January 21, 2014, accepted January 28, 2014.
J A C C V O L . 6 4 , N O . 1 1 , 2 0 1 4 Damman et al.
S E P T E M B E R 1 6 , 2 0 1 4 : 1 1 0 6 – 1 3 ARB Impact on HFpEF With Worsening Renal Function
1107AB BR E V I A T I O N S
AND ACRONYM S
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
MAP = mean arterial blood
pressure
MRA = mineralocorticoid
receptor antagonist
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
RAAS = renin-angiotensin-
aldosterone system
SCr = serum creatinine
WRF = worsening renal
functionD eterioration of renal function over time,termed worsening renal function (WRF), isassociated with worse outcomes in patients
with acute and chronic heart failure (HF) (1). Although
this association has been established in patients with
HF with reduced ejection fraction (HFrEF), no data
exist regarding the relationship betweenWRF and out-
comes in HF patients with preserved ejection fraction
(HFpEF). Furthermore, controversy persists about
whether WRF is always associated with poor outcome.
Recent studies suggest that the cause of renal function
decline, the circumstances under which it occurs, and
the concomitant therapy used may be far more impor-
tant than the actual occurrence of WRF itself (2–4).
Notably, WRF after initiation of renin-angiotensin-
aldosterone system (RAAS) inhibitors in clinical trials
has not been associated with poor outcome, but WRF
is prognostic when it occurs in the placebo group
(5–8). Furthermore, the beneﬁt associated with RAAS
blockade was observed in both patients with and
without WRF, implying that WRF does not alter the
beneﬁt of therapy.SEE PAGE 1114In the present study, we investigated change in
estimated glomerular ﬁltration rate (eGFR) over time,
the occurrence of WRF and its association with
clinical outcomes, and interaction with randomized
treatment in patients with HFpEF included in the
I-PRESERVE (Irbesartan in Heart Failure With Pre-
served Ejection Fraction) trial.
PATIENTS AND METHODS
The design and results of I-PRESERVE have been
published previously (9). In brief, 4,128 patients $60
years of age, with signs and symptoms of HF and a
preserved left ventricular ejection fraction ($45%)
were randomized to receive placebo or irbesartan
300 mg once daily. Patients were started on 75 mg of
irbesartan or placebo once daily. The dose was
doubled to 150 mg after 1 to 2 weeks and doubled
again to 300 mg after an additional 1 to 2 weeks, as
tolerated. Patients with a baseline serum creatinine
(SCr) level >221 mmol/l (2.5 mg/dl) were excluded
from the study. Patients with an SCr measurement at
baseline and at the visit 8 weeks after randomization
were included in the present analysis.
GFR AND WRF. The eGFR was calculated by using the
simpliﬁed Modiﬁcation of Diet in Renal Disease for-
mula at baseline and subsequent visits (2 and 8 weeks
and 6, 18, and 30 months). WRF was deﬁned as an
absolute increase in SCr of $26.5 mmol/l ($0.3 mg/dl),
together with a relative increase in SCr of $25%between baseline and 8 weeks (the period
during which forced titration of randomized
treatment occurred). In addition, as sensi-
tivity analyses, we also calculated WRF
deﬁned as an absolute increase in SCr $26.5
mmol/l or a reduction in eGFR $20%, all at 8
weeks. Finally, we assessed early WRF 2
weeks after randomization for each
deﬁnition.
OUTCOMES. For the present analysis, the
primary outcome was the ﬁrst occurrence of
cardiovascular death or HF hospitalization.
Secondary outcomes included all-cause mor-
tality, HF hospitalization, the combined
endpoint of all-cause mortality or HF
hospitalization, and the primary endpoint of
the I-PRESERVE trial, which was the com-
posite of all-cause mortality or ﬁrst hospital-
ization for a protocol-speciﬁed adjudicated
cardiovascular hospitalization (deﬁned as worsening
HF, unstable angina, myocardial infarction, ventric-
ular arrhythmia, atrial arrhythmia, or stroke). All
outcomes were adjudicated by an independent clin-
ical endpoint committee.
STATISTICAL ANALYSIS. Data are reported as
mean  SD when normally distributed, as median and
interquartile ranges when the distribution was
skewed, and as frequencies and percentages for
categorical variables. The Student t test or Mann-
Whitney U tests were used to determine signiﬁcant
differences in variables between patients with and
without WRF in both treatment groups. Logistic
regression was used to determine odds ratios for the
occurrence of WRF at 8 weeks. Change in renal fun-
ction over time was assessed by using repeated anal-
ysis mixed-effect modeling. Multivariable modeling
was adjusted for variables previously shown to be of
prognostic value in this population (10).
Covariates adjusted for as ﬁxed effects were: age;
sex; race; etiology of HF; New York Heart Association
functional class; left ventricular ejection fraction;
systolic and diastolic blood pressures; heart rate;
history of myocardial infarction, hypertension, atrial
ﬁbrillation, stroke, and diabetes; baseline medical
therapy (angiotensin-converting enzyme inhibitor,
beta-blocker, diuretics, digoxin, and spironolactone);
and measurement of N-terminal pro–B-type natri-
uretic peptide (NT-proBNP, logarithmically trans-
formed). Patients were included as random effects,
and time was modeled linearly. A Cox proportional
hazards model was used to estimate hazard ratios
with 95% conﬁdence intervals for the occurrence of
the primary and all secondary endpoints. WRF was
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Interaction terms with treatment (WRF  treatment)
were analyzed for each deﬁnition of WRF separately.
Kaplan-Meier survival curves were plotted showing
outcomes in patients who did or did not ex-
perience WRF in both treatment groups. A 2-tailed
p value <0.05 was considered signiﬁcant, except for
interactions in which p < 0.10 was considered sig-
niﬁcant. We chose a liberal cutoff point for the
p value of signiﬁcant interactions to allow better
discrimination between false-negative and clinically
signiﬁcant interactions in light of the low event rates.
Statistical analyses were performed by using Stata
version 12.0 (Stata Corp., College Station, Texas).
RESULTS
A total of 3,595 patients (87% of all randomized pa-
tients) with an SCr measurement available at both
baseline and 8 weeks formed the study population.TABLE 1 Baseline Characteristics of Patients With and Without WRF
Irbesartan
WRF No WRF
Patients 153 (8) 1,659 (92)
Age, yrs 73  7 71  7
Male 76 (50) 647 (39)
Heart rate, beats/min 73  10 72  11
SBP, mm Hg 138  17 137  15
DBP, mm Hg 79  9 79  9
BMI, kg/m2 30  6 30  5
LVEF, % 58  8 60  9
Ischemic HF 39 (25) 427 (26)
Medical history
Hypertension 86 90
Diabetes 34 26
Atrial ﬁbrillation 37 28
Stroke 10 9
Myocardial infarction 27 23
Laboratory
Hemoglobin, g/dl 13.9  1.5 14.0  1.5
Creatinine, mmol/l* 92  30 88  28
eGFR, ml/min/1.73 m2 74  29 73  21
NT-proBNP, pg/ml 1,163 (177–1,238) 854 (136–942)
Medical therapy
ACE inhibitors 29 25
MRAs 27 14
Loop diuretics* 70 51
Beta-blockers 61 60
NSAIDs 7 8
Digoxin 16 14
Values are n (%), mean  SD, %, or median (interquartile range). *Signiﬁcant interactio
ACE ¼ angiotensin-converting enzyme; BMI ¼ body mass index; DBP ¼ diastolic blood
ventricular ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NSAIDs ¼ no
peptide; SBP ¼ systolic blood pressure; WRF ¼ worsening renal function.Baseline characteristics are shown in Table 1.
Compared with the entire I-PRESERVE study popu-
lation, these patients had a slightly higher mean
baseline SCr level but a similar eGFR, were more
frequently male, and more often had ischemic heart
disease, diabetes, and atrial ﬁbrillation (data not
shown).
CHANGE IN EGFR AND WRF. During the study, mean
eGFR decreased from 73  23 to 68  21 ml/min/
1.73 m2 at 30 months. This ﬁnding translates into a
change in eGFR of –2.2  7.3 ml/min/1.73 m2 per year.
Figure 1 displays the trends of eGFR over time in pa-
tients randomized to receive placebo or irbesartan. A
signiﬁcant difference between the 2 treatment groups
persisted throughout the entire study period. The
mean overall decrease in eGFR in the placebo group
was –3.4  23 ml/min/1.73 m2 versus –7.2  23 ml/min/
1.73 m2 in the irbesartan group (p < 0.001) at 30
months. Patients in the irbesartan group experienced
a rapid, small initial decrease in eGFR; both groupsPlacebo
p Value WRF No WRF p Value
76 (4) 1,707 (96)
0.06 72  7 72  7 0.42
0.001 32 (42) 647 (38) 0.46
0.17 73  11 71  10 0.02
0.60 137  18 136  15 0.36
0.87 80  10 79  9 0.36
0.31 30  7 29  5 0.15
0.02 59  8 60  9 0.55
0.46 11 (14) 407 (24) 0.37
0.14 89 88 0.74
0.038 38 26 0.024
0.026 29 29 0.94
0.64 4 9 0.10
0.25 18 23 0.36
0.40 13.8  1.6 14.0  1.5 0.19
0.11 84  26 88  28 0.19
0.60 78  27 73  23 0.03
0.019 843 (138–992) 786 (128–928) 0.98
0.29 25 24 0.80
<0.001 24 14 0.026
<0.001 53 52 0.91
0.77 53 59 0.29
0.66 12 8 0.30
0.33 16 13 0.46
n between WRF and treatment allocation.
pressure; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; LVEF ¼ left
nsteroidal anti-inﬂammatory drugs; NT-proBNP ¼ N-terminal pro–B-type natriuretic
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FIGURE 1 Change in eGFR Over Time Stratiﬁed According to
Randomized Treatment Allocation
Presented are least squares means  SEs from adjusted mixed-
effects repeated measurements model. Patients were considered
a random effect and the following were ﬁxed effects: age; sex;
race; etiology of heart failure; New York Heart Association
functional class; left ventricular ejection fraction; systolic and
diastolic blood pressures; heart rate; history of myocardial
infarction, hypertension, atrial ﬁbrillation, stroke, or diabetes;
baseline medical therapy (angiotensin-converting enzyme
inhibitor, beta-blocker, diuretics, digoxin, and spironolactone
use); and N-terminal pro–B-type natriuretic peptide measure-
ment. $p < 0.050, #p < 0.01, *p < 0.001. For overall interac-
tion, p <0.001. eGFR ¼ estimated glomerular ﬁltration rate.
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over time (p for interaction time and allocated
treatment <0.001).
WRF at 8 weeks developed in 229 (6.4%) patients.
Patients randomized to irbesartan treatment experi-
enced WRF more often (8.4% vs. 4.3%; odds ratio:
2.07; 95% conﬁdence interval: 1.56 to 2.75; p < 0.001).
The incidence of WRF according to the other pre-
speciﬁed deﬁnitions is presented in Online Table 1.
WRF at 2 weeks was less frequent compared with the
occurrence at 8 weeks. Clinical characteristics of pa-
tients with WRF according to treatment allocation are
presented in Table 1. In general, there were few dif-
ferences between patients with and without WRF; the
main differences were presence of diabetes, higher
NT-proBNP concentrations, use of diuretics, and
treatment with a mineralocorticoid receptor antago-
nist (MRA). These differences were more pronounced
in patients allocated to irbesartan treatment,
although the only signiﬁcant interaction between
WRF and treatment allocation was seen for baseline
SCr level and diuretic treatment.
Patients who experienced WRF at week 8
had similar discontinuation rates of randomizedtreatment at weeks 2 and 8. Overall, study drug
discontinuation rates were very low, with no differ-
ence observed between the placebo and irbesartan
groups. Occurrence of WRF was not associated with
changes in either MRA or loop diuretic therapy. In the
irbesartan group, patients developing WRF exhibited
a signiﬁcantly greater reduction in mean arterial
blood pressure (MAP) at week 8 (–6.8  11 mm Hg)
compared with those who did not experience WRF
(–4.0  11 mm Hg; p ¼ 0.003). In the placebo group,
the reduction in MAP at week 8 was similar in those
with and without WRF (–2.0  12 mm Hg vs. –1.6 
11 mm Hg; p ¼ 0.76). The decrease in MAP in patients
developing WRF in the irbesartan group was signiﬁ-
cantly larger than the fall in MAP in those developing
WRF in the placebo group (p ¼ 0.003). In a mixed-
effect linear model, changes in MAP showed a sig-
niﬁcant positive association with changes in eGFR
over time, and there was a signiﬁcant multivariate
adjusted interaction between irbesartan treatment
allocation, changes in MAP, and change in eGFR over
time (p ¼ 0.004).
WRF, IRBESARTAN TREATMENT, AND OUTCOME.
During a mean follow-up of 46 months, the primary
outcome (cardiovascular death or HF hospitalization)
occurred in 895 patients. A total of 85 patients (37%)
with WRF and 810 patients (24%) without WRF
reached the combined endpoint. WRF was associated
with an increased risk of developing the primary
outcome (univariate hazard ratio: 1.75; 95% conﬁ-
dence interval: 1.41 to 2.17; p < 0.001). In the
univariate analyses, WRF deﬁned in the various pre-
speciﬁed methods was consistently related to a poor
outcome, as documented in Table 2 and Online
Table 1.
However deﬁned, WRF befalling patients allocated
to irbesartan treatment was associated with more
frequent occurrence of the primary outcome. The
only exception was a decrease in eGFR at 2 weeks.
Importantly, in the main analysis, treatment alloca-
tion interacted with the relationship between WRF
and outcome: WRF exhibited a stronger relationship
with outcome in the irbesartan group (Central
Illustration). In multivariable analysis, WRF was
associated with the primary outcome in the overall
population and the irbesartan treatment group but
not the placebo group (Table 3, Online Table 2). In
addition, WRF was strongly associated with all sec-
ondary outcomes, with a similar magnitude of asso-
ciation (Table 4, Online Table 3). After multivariable
adjustment, the interaction between treatment allo-
cation and WRF on the effect of cardiovascular death
or HF hospitalization was no longer signiﬁcant,
although it remained so for all-cause mortality,
CENTRAL ILLUST
Stratiﬁed According
The Central Illustrat
function (WRF), rand
death or heart failur
and no WRF, HR: 1.1
and no WRF; HR: 1.4
1.97 (95% CI: 1.51 to
TABLE 2 Univariate Analysis: WRF and Cardiovascular Death and HF Hospitalizations
Overall
Incidence (%)
OR for WRF With
Irbesartan p Value
Overall Placebo Irbesartan
p Value
Interaction*HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
$0.3 mg/dl and $25% increase
in creatinine
229 (6.4) 2.07 (1.56–2.75) <0.001 1.75 (1.41–2.17) <0.001 1.27 (0.85–1.93) 0.25 1.97 (1.50–2.58) <0.001 0.084
$0.3 mg/d increase in creatinine 245 (6.8) 2.13 (1.62–2.80) <0.001 1.84 (1.49–2.26) <0.001 1.32 (0.89–1.96) 0.17 2.10 (1.62–2.72) <0.001 0.055
$20% decrease in eGFR 412 (11.5) 1.82 (1.47–2.25) <0.001 1.35 (1.12–1.62) 0.002 1.25 (0.92–1.69) 0.16 1.33 (1.04–1.70) 0.021 0.72
*Interaction between WRF and treatment on outcome. WRF deﬁned at 8 weeks.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; OR ¼ odds ratio; other abbreviations as in Table 1.
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1110all-cause mortality or HF hospitalization, and the
primary outcome of I-PRESERVE. No interactions
occurred between either baseline NT-proBNP or
diuretic use or MRA use, and the relationship be-
tween WRF, treatment, and outcome. WRF deﬁned
by changes up to 2 weeks were not independently
associated with outcome, and none of the interaction
terms between treatment and WRF was signiﬁcant.
DISCUSSION
In the present study, we found that WRF occurred
more frequently in patients allocated to treatment
with irbesartan compared with placebo. Overall, the
occurrence of WRF was associated with worse clinical
outcomes compared with no WRF. This associationRATION Kaplan-Meier Curve: CV Death and HF Hospitalization
to Treatment and WRF
ion shows the relationship between occurrence of worsening renal
omized treatment, and the ﬁrst occurrence of cardiovascular (CV)
e (HF) hospitalization. Univariate hazard ratio (HR) versus irbesartan
4 (95% conﬁdence interval [CI]: 1.00 to 1.31), p ¼ 0.057 for placebo
6 (95% CI: 0.97 to 2.20), p ¼ 0.073 for placebo and WRF; and HR:
2.58), p < 0.001 for irbesartan and WRF, respectively.seemed to be stronger in patients receiving irbesartan
compared with placebo, contrasting strikingly with
studies of RAAS inhibition in HFrEF (7,8,13).
WRF IN HFPEF AND HFREF. A large number of
epidemiological studies in acute and chronic HF have
shown an association between the development of
WRF and poor clinical outcomes, including death
(1,4–6,11–13). However, recent data from randomized
clinical trials in HFrEF patients as well as studies in
acute HF have questioned this association. In acute
HF, WRF does not always portend a poor prognosis.
In clinical trials, WRF was not associated with
poor outcomes unless patients saw no decrease in
systolic blood pressure or persistent congestion (2,4).
Furthermore, although more intense diuretic treat-
ment may lead to (transient) increases in SCr, such
treatment is not associated with excess mortality (14).
These observations suggest that it is not the devel-
opment of WRF per se that is important but the
circumstances under which it develops (or what
causes it).
The present study differs from earlier observa-
tions because we investigated a chronic HFpEF
population, which, to our knowledge, has not been
studied before. One study did, however, investigate
WRF developing in HFpEF patients admitted for
HF. In that study, Rusinaru et al. (15) found that
in-hospital WRF was predictive of 7-year outcome
but only in patients with a reduced eGFR at baseline.
To date, no substudy is available from the
CHARM (Candesartan in Heart Failure Assessment of
Reduction in Mortality and Morbidity) study, but an
earlier study found no interaction between baseline
renal function and type of HF (HFpEF vs. HFrEF)
(16). In the present study, we found that in patients
with clinically stable HFpEF, WRF at 8 weeks was
independently associated with all cardiovascular
outcomes examined and all-cause mortality. There-
fore, the overall association between WRF and poor
clinical outcomes in chronic HFpEF seems compa-
rable to HFrEF and acute HF.
TABLE 3 Multivariable Analysis: WRF and Cardiovascular Death and HF Hospitalizations
Overall Placebo Irbesartan
p Value
Interaction*HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
$0.3 mg/dl and $25% increase in creatinine 1.43 (1.10–1.85) 0.008 1.09 (0.66–1.79) 0.73 1.66 (1.21–2.28) 0.002 0.13
$0.3 mg/dl increase in creatinine 1.41 (1.09–1.83) 0.009 1.19 (0.74–1.90) 0.48 1.57 (1.14–2.15) 0.005 0.26
$20% decrease in eGFR 1.35 (1.08–1.69) 0.009 1.37 (0.95–1.99) 0.089 1.36 (1.01–1.82) 0.041 0.94
*Interaction between WRF and treatment on outcome. WRF deﬁned at 8 weeks.
Abbreviations as in Tables 1 and 2.
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1111RAAS INHIBITION, WRF, AND OUTCOME. It has long
been known that initiation of a RAAS inhibitor may
lead to an increase in SCr (and a decrease in eGFR),
which is usually small (17). This is thought to occur
because RAAS activation in HF leads to glomerular
efferent arteriolar vasoconstriction that preserves
GFR in the face of a fall in glomerular perfusion
pressure. RAAS blockers can reduce glomerular
perfusion pressure (by reducing systemic arterial
and afferent arteriolar pressure while simultaneously
preventing compensatory efferent arteriolar con-
striction). However, in the long run, angiotensin-
converting enzyme inhibitor and angiotensin
receptor blocker treatment seems to preserve or, in
certain populations, attenuate decreases in eGFR,
suggesting that any initial decline in GFR may not be
clinically relevant (18–20). It could even be argued
that the initial decrease in eGFR with RAAS inhibition
serves as a marker of RAAS activation intensity and,
therefore, potentially is a more favorable response to
therapy. These hypotheses have been tested inTABLE 4 WRF and Primary and Secondary Outcomes
CV Death/HF Hospitalization
Events
(n/N) HR (95% CI) p Value
Univariate
WRF* 85/229 1.75 (1.41–2.17) <0.001
Irbesartan 61/153 1.97 (1.50–2.58) <0.001
Placebo 24/76 1.27 (0.85–1.93) 0.25
p value interaction 0.084
Multivariate
WRF* 85/229 1.43 (1.10–1.85) 0.008
Irbesartan 61/153 1.66 (1.21–2.28) 0.002
Placebo 24/76 1.09 (0.66–1.79) 0.73
p value interaction 0.13
Interaction
Irbesartan and no WRF* 378/1659 Ref. 3
Irbesartan and WRF* 61/153 1.68 (1.23–2.31) 0.001
Placebo and no WRF* 432/1707 1.15 (0.97–1.36) 0.15 3
Placebo and WRF* 24/76 1.23 (0.75–2.02) 0.41
*WRF is deﬁned as $0.3 mg/dl and $25% increase in creatinine.
CV ¼ cardiovascular; other abbreviations as in Tables 1 and 2.retrospective analyses of multiple HFrEF/left ven-
tricular dysfunction trials. In the SAVE (Survival and
Ventricular Enlargement) trial, patients developing
WRF with captopril treatment experienced a better
outcome than patients developing WRF with placebo
(and even better than in patients receiving placebo
not developing WRF) (11). In an analysis of the
2 SOLVD (Studies of Left Ventricular Dysfunction)
trials, Testani et al. (5) found that only WRF occurring
with placebo was associated with mortality, whereas
patients developing WRF while taking enalapril had
the best outcome. Similar data exist for angiotensin
receptor blockers and MRAs (6–8).
In the context of these previous studies, our ﬁnd-
ings in patients with HFpEF show some remarkable
similarities and differences. First, depending on the
deﬁnition used, WRF occurred in 6.0% to 14.4% of
patients allocated to the irbesartan group, consistent
with previous studies in HFrEF in which the inci-
dence was approximately 6% to 10% after starting
an angiotensin-converting enzyme inhibitor orAll-Cause Death HF Hospitalization
Events
(n/N) HR (95% CI) p Value
Events
(n/N) HR (95% CI) p Value
72/229 1.63 (1.28–2.08) <0.001 60/229 1.85 (1.41–2.41) <0.001
53/153 1.94 (1.45–2.59) <0.001 42/153 2.10 (1.51–2.91) <0.001
19/76 1.18 (0.74–1.87) 0.49 18/76 1.53 (0.95–2.46) 0.082
0.073 0.28
72/229 1.41 (1.05–1.88) 0.020 60/229 1.49 (1.08–2.05) 0.002
53/153 1.72 (1.22–2.43) 0.002 42/153 1.61 (1.08–2.38) 0.018
19/76 0.99 (0.57–1.71) 0.97 18/76 1.30 (0.73–2.30) 0.37
0.078 0.52
20/1659 Ref. 240/1659 Ref.
53/153 1.74 (1.23–2.45) 0.002 42/153 1.63 (1.10–2.41) 0.014
52/1707 1.19 (0.98–1.44) 0.073 273/1707 1.10 (0.89–1.35) 0.40
19/76 1.16 (0.67–2.00) 0.60 18/76 1.43 (0.81–2.52) 0.22
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with heart failure and reduced left ventricular
ejection fraction, treatment with inhibitors of the
renin-angiotensin-aldosterone system may cause
worsening of renal function despite systemic hemo-
dynamic improvement.
TRANSLATIONAL OUTLOOK: The mechanisms
responsible for deterioration of renal function in some
patients with heart failure and preserved ejection
fraction during treatment with renin-angiotensin-
aldosterone system inhibitors, and the associated
worsening of prognosis that parallels the decline in
renal function, require further investigation.
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1112angiotensin receptor blocker (and somewhat higher,
at around 15%, with an MRA) (5–8). Second, initiation
of a RAAS inhibitor results in an immediate but
limited fall in eGFR, although thereafter eGFR falls
gradually over time, at a similar rate to that in the
placebo group. We also found that across the whole
I-PRESERVE population, WRF was associated with
poor outcome, as alluded to earlier.
However, WRF occurring after initiation of
irbesartan treatment in patients with HFpEF was
associated with considerably higher event rates,
independent of other risk factors (a relationship not
apparent in the placebo group). This ﬁnding directly
contrasts with the ﬁndings from SOLVD and Val-
HeFT (Valsartan Heart Failure Trial) in patients
with HFrEF (5,8,21), although it is unclear why this
discrepancy exists. There are some obvious differ-
ences between the trials: irbesartan did not improve
outcome in I-PRESERVE, whereas both enalapril
and valsartan did in SOLVD and Val-HeFT, respec-
tively. Theoretically, the ﬁndings with angiotensin-
converting enzyme inhibitors and angiotensin
receptor blockers in HFrEF could represent the
summed result of a negative effect of WRF out-
weighed by other positive effects of RAAS inhibition,
resulting in a net positive effect on outcome. Because
irbesartan did not improve any clinical outcome in
I-PRESERVE, perhaps the negative effect of WRF was
not counterbalanced sufﬁciently by the potentially
positive effects of angiotensin receptor blocker
treatment. Indeed, even patients who did not
develop WRF in I-PRESERVE demonstrated no sug-
gestion of improved outcome. It could also be that
the WRF observed after RAAS blockade in patients
with HFpEF reﬂects a different and more harmful
process than WRF in HFrEF.
We found that blood pressure reduction with
irbesartan was more pronounced in the WRF group
and even greater compared with the blood pressure
reduction in patients taking placebo who developed
WRF. This ﬁnding suggests a possible reason for WRF
occurrence with irbesartan but not necessarily the
reason for the poor outcome. In addition, we
observed signiﬁcant associations between changes in
MAP and eGFR, as well as a signiﬁcant interaction
among irbesartan, changes in MAP, and changes in
eGFR. This contrasts with ﬁndings from the literature
on RAAS inhibitors in patients without HF, in which
greater blood pressure reductions were associated
with a lower incidence of renal endpoints (20).
Finally, NT-proBNP levels were higher in patients
experiencing WRF in the irbesartan group. This
ﬁnding could represent more pronounced venous
congestion and increased renal venous pressure and,together with a decrease in MAP, could have reduced
renal perfusion pressure substantially, with subse-
quent reduction in eGFR and increase in salt and
water retention leading to poor clinical outcome (22).
Future investigation of the epidemiology, patho-
physiology, and treatment of HFpEF should take
renal function into account.
STUDY LIMITATIONS. As a retrospective analysis of a
clinical trial, observations from this study may not
apply to the general HFpEF population. More impor-
tantly, I-PRESERVE demonstrated no overall effect of
irbesartan treatment on outcome, and therefore
analyses of subsets of patients should be regarded as
hypothesis generating. For reasons unknown, repeat
SCr values were not available for all patients, poten-
tially resulting in bias, although this was the case in
only a small proportion of patients. We should also
consider the possibility that the observed associa-
tions are in fact chance ﬁndings given that the
number of events in this HFpEF patient population
was limited.
CONCLUSIONS
The incidence of WRF after initiation of an angio-
tensin receptor blocker in HFpEF was similar to that
observed previously in HFrEF but, in contrast to
patients with HFrEF, it was associated with poorer
clinical outcomes.
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